Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2002 | 1 |
2003 | 1 |
2017 | 1 |
2021 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
ZNF703 mRNA-Targeting Antisense Oligonucleotide Blocks Cell Proliferation and Induces Apoptosis in Breast Cancer Cell Lines.
Pharmaceutics. 2023 Jul 11;15(7):1930. doi: 10.3390/pharmaceutics15071930.
Pharmaceutics. 2023.
PMID: 37514116
Free PMC article.
Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.
Doghri R, Manai M, Finetti P, Driss M, Agavnian E, Lopez M, Elghardallou M, Charafe-Jauffret E, Manai M, Chaffanet M, Birnbaum D, Mrad K, Bertucci F.
Doghri R, et al. Among authors: chaffanet m.
Int J Mol Sci. 2017 Dec 23;19(1):41. doi: 10.3390/ijms19010041.
Int J Mol Sci. 2017.
PMID: 29295532
Free PMC article.
Item in Clipboard
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
Vicier C, Sfumato P, Isambert N, Dalenc F, Robert M, Levy C, Rezai K, Provansal M, Adélaïde J, Garnier S, Guille A, Carbuccia N, Popovici C, Charafe-Jauffret E, Chaffanet M, Birnbaum D, Pakradouni J, Bertucci F, Boher JM, Sabatier R, Gonçalves A.
Vicier C, et al. Among authors: chaffanet m.
Eur J Cancer. 2021 Dec;159:205-214. doi: 10.1016/j.ejca.2021.09.040. Epub 2021 Nov 12.
Eur J Cancer. 2021.
PMID: 34781168
Clinical Trial.
RESULTS: A total of 51 patients were enrolled; RP2D was LY2780301 500 mg QD+ paclitaxel 80 mg/m(2). Main drug-related adverse events noted in phase Ib included neuropathy (75% of patients, grade 3-4 in 8%), asthenia (58% of patients, no grade 3-4), and ungual toxicity (50% …
RESULTS: A total of 51 patients were enrolled; RP2D was LY2780301 500 mg QD+ paclitaxel 80 mg/m(2). Main drug-related adverse events …
Item in Clipboard
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Popovici C, Basset C, Bertucci F, Orsetti B, Adélaide J, Mozziconacci MJ, Conte N, Murati A, Ginestier C, Charafe-Jauffret E, Ethier SP, Lafage-Pochitaloff M, Theillet C, Birnbaum D, Chaffanet M.
Popovici C, et al. Among authors: chaffanet m.
Genes Chromosomes Cancer. 2002 Nov;35(3):204-18. doi: 10.1002/gcc.10107.
Genes Chromosomes Cancer. 2002.
PMID: 12353263
We surveyed 15 mammary cell lines by multicolor fluorescence in situ hybridization (M-FISH). We identified nine apparently reciprocal translocations. ...
We surveyed 15 mammary cell lines by multicolor fluorescence in situ hybridization (M-FISH). We identified nine apparently reciprocal …
Item in Clipboard
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Adélaïde J, Huang HE, Murati A, Alsop AE, Orsetti B, Mozziconacci MJ, Popovici C, Ginestier C, Letessier A, Basset C, Courtay-Cahen C, Jacquemier J, Theillet C, Birnbaum D, Edwards PA, Chaffanet M.
Adélaïde J, et al. Among authors: chaffanet m.
Genes Chromosomes Cancer. 2003 Aug;37(4):333-45. doi: 10.1002/gcc.10218.
Genes Chromosomes Cancer. 2003.
PMID: 12800145
We surveyed 34 breast tumor cell lines and 9 pancreatic cancer cell lines for alterations of this region by use of multicolor fluorescence in situ hybridization (M-FISH) and BAC-specific FISH. We describe a recurrent chromosome translocation breakpoint that targets the NRG …
We surveyed 34 breast tumor cell lines and 9 pancreatic cancer cell lines for alterations of this region by use of multicolor fluorescence i …
Item in Clipboard
Cite
Cite